If You Invested in Tema Oncology ETF (CANC)

Tema Oncology ETF (ticker symbol CANC) is an exchange-traded fund managed by Tema ETFs that focuses on the oncology segment of the healthcare and biotechnology markets. According to Tema ETFs, the fund invests in oncology companies and cancer therapies and is described as a pure-play oncology focused ETF, meaning its investment universe is centered on businesses involved in the fight against cancer.

The CANC ETF is actively managed by Tema ETFs, a New York-based active ETF investment manager. The fund is overseen by portfolio manager Dr. David Song, MD, PhD, CFA, whose background combines medical training and a long-standing career in healthcare investing. Tema states that CANC was designed to use this experience to provide investors with access to companies that are at the forefront of oncology and cancer treatment development.

Oncology is highlighted by Tema as one of the largest and fastest-growing areas of innovation within healthcare, reflecting the ongoing global impact of cancer. The fund’s strategy focuses on oncology-related companies, which may include firms involved in the development, procurement and marketing of oncology drugs and therapies, as well as those whose business models depend heavily on intellectual property in this field. The disclosures for CANC emphasize that oncology companies can be affected by factors such as product safety, effectiveness, profitability, and regulatory approvals.

The fund is subject to industry concentration risk because its assets are focused on a specific industry group. Tema notes that this can expose investors to losses if adverse events affect oncology or related biotechnology industries. The disclosures also highlight biotechnology industry risk, including exposure to patent issues, competition, rapid technological change, government regulation and product liability concerns. These factors can contribute to volatility in the share prices of companies held by the fund.

In addition to oncology and biotechnology risks, CANC’s disclosures reference risks associated with investing in foreign and emerging markets, such as political, economic and regulatory conditions, as well as currency risk. The fund also evaluates environmental, social and governance (ESG) factors to assess and exclude certain investments for non-financial reasons, which may mean that CANC does not participate in some opportunities available to funds that do not use ESG criteria.

Tema ETFs, the adviser to the fund, describes itself as an active ETF investment manager founded to offer durable and strategic portfolio solutions across quality, core, thematic and alternative strategies. Tema Oncology ETF is one of its thematic offerings, focused specifically on oncology. NEOS Investments, LLC serves as a sub-adviser to the fund, and Foreside Fund Services LLC acts as distributor, as disclosed in the fund information.

The fund’s materials stress that investing involves risk, including the possible loss of principal, and that there is no guarantee that the adviser’s investment strategy will be successful. They also note that performance data represent past performance and do not guarantee future results, and that the value of an investor’s shares can fluctuate over time. Investors are directed in the disclosures to review the fund’s prospectus or summary prospectus for detailed information on objectives, risks, charges and expenses.